AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 15, 2026

Daily Signals

2696 companies scored · 2026-10-15 run in progress: 5121 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-15 Cut-offs from the 2026-10-15 run
Companies scored 2696 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.29% Alpha · 90D
Long–short spread +5.09% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 557 ▼ 696 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

304 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
151 TYRATyra Biosciences, Inc. Life Sciences 0.22 $1.1B Unlock rating and forecasts
152 LBRXLB PHARMACEUTICALS INC Life Sciences 0.20 $1.1B Unlock rating and forecasts
153 REPLReplimune Group, Inc. Life Sciences 0.36 $1.1B Unlock rating and forecasts
154 MNKDMANNKIND CORP Life Sciences 0.62 $971M Unlock rating and forecasts
155 QDELQuidelOrtho Corp Life Sciences 0.05 $951M Unlock rating and forecasts
156 IMTXImmatics N.V. Life Sciences 0.34 $938M Unlock rating and forecasts
157 MGTXMeiraGTx Holdings plc Life Sciences 0.30 $904M Neutral -0.39% -0.85% ·
158 CGEMCullinan Therapeutics, Inc. Life Sciences 0.40 $901M Unlock rating and forecasts
159 ANROAlto Neuroscience, Inc. Life Sciences 0.21 $888M Unlock rating and forecasts
160 RIGLRIGEL PHARMACEUTICALS INC Life Sciences 0.06 $875M Neutral -0.15% -0.26% ▼ 2
161 CYRXCryoport, Inc. Life Sciences 0.30 $865M Neutral -0.16% -0.28% ▼ 1
162 ABUSArbutus Biopharma Corp Life Sciences 0.05 $849M Unlock rating and forecasts
163 GLUEMonte Rosa Therapeutics, Inc. Life Sciences 0.15 $839M Unlock rating and forecasts
164 AVBPArriVent BioPharma, Inc. Life Sciences 0.18 $828M Unlock rating and forecasts
165 ALMSALUMIS INC. Life Sciences 0.28 $817M Unlock rating and forecasts
166 ARDXARDELYX, INC. Life Sciences 0.38 $815M Neutral -0.28% -0.55% ▼ 2
167 DNAGinkgo Bioworks Holdings, Inc. Life Sciences 0.30 $792M Unlock rating and forecasts
168 HELPHelus Pharma Inc. Life Sciences 0.18 $782M Unlock rating and forecasts
169 GERNGERON CORP Life Sciences 0.10 $765M Unlock rating and forecasts
170 COLLCOLLEGIUM PHARMACEUTICAL, INC Life Sciences 0.63 $755M Unlock rating and forecasts
171 IVAInventiva S.A. Life Sciences 0.24 $749M Unlock rating and forecasts
172 ACHVACHIEVE LIFE SCIENCES, INC. Life Sciences 0.40 $717M Unlock rating and forecasts
173 LXRXLEXICON PHARMACEUTICALS, INC. Life Sciences 0.43 $712M Neutral +0.02% +0.07% ▼ 1
174 IMMXImmix Biopharma, Inc. Life Sciences 0.29 $706M Unlock rating and forecasts
175 GYREGYRE THERAPEUTICS, INC. Life Sciences 0.02 $699M Unlock rating and forecasts
176 VSTMVerastem, Inc. Life Sciences 0.47 $698M Unlock rating and forecasts
177 SANASana Biotechnology, Inc. Life Sciences 0.28 $698M Unlock rating and forecasts
178 ANNXAnnexon, Inc. Life Sciences 0.31 $682M Unlock rating and forecasts
179 CADLCandel Therapeutics, Inc. Life Sciences 0.41 $682M Unlock rating and forecasts
180 FDMT4D Molecular Therapeutics, Inc. Life Sciences 0.22 $674M Unlock rating and forecasts
181 AURAAura Biosciences, Inc. Life Sciences 0.43 $657M Unlock rating and forecasts
182 DSGNDesign Therapeutics, Inc. Life Sciences 0.24 $656M Unlock rating and forecasts
183 AVTXAvalo Therapeutics, Inc. Life Sciences 0.29 $644M Unlock rating and forecasts
184 CLYMClimb Bio, Inc. Life Sciences 0.45 $627M Unlock rating and forecasts
185 WVEWave Life Sciences, Inc. Life Sciences 0.50 $609M Unlock rating and forecasts
186 ZVRAZEVRA THERAPEUTICS, INC. Life Sciences 0.28 $608M Unlock rating and forecasts
187 PHATPhathom Pharmaceuticals, Inc. Life Sciences 0.17 $599M Unlock rating and forecasts
188 OLMAOlema Pharmaceuticals, Inc. Life Sciences 0.25 $595M Unlock rating and forecasts
189 IRWDIRONWOOD PHARMACEUTICALS INC Life Sciences 0.22 $595M Unlock rating and forecasts
190 SLDBSolid Biosciences Inc. Life Sciences 0.13 $586M Unlock rating and forecasts
191 CRMDCorMedix Inc. Life Sciences 0.19 $581M Neutral -0.36% -0.74% ▲ 1
192 PRMEPrime Medicine, Inc. Life Sciences 0.20 $568M Unlock rating and forecasts
193 DBVTDBV Technologies S.A. Life Sciences 0.36 $539M Neutral -0.37% -0.76% ▲ 1
194 STTKShattuck Labs, Inc. Life Sciences 0.35 $535M Unlock rating and forecasts
195 CBIOGYRE THERAPEUTICS, INC. Life Sciences 0.10 $534M Unlock rating and forecasts
196 CTMXCytomX Therapeutics, Inc. Life Sciences 0.07 $525M Unlock rating and forecasts
197 DRUGBRIGHT MINDS BIOSCIENCES INC. Life Sciences 0.22 $524M Unlock rating and forecasts
198 FTHFaeth Therapeutics, Inc. Life Sciences 0.06 $517M Neutral -0.14% -0.24% ▼ 2
199 ACRSAclaris Therapeutics, Inc. Life Sciences 0.35 $514M Unlock rating and forecasts
200 EOLSEvolus, Inc. Life Sciences 0.50 $477M Unlock rating and forecasts
151–200 of 304 Previous Next
Since the previous run

Rating changes

▲ 557▼ 696
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.